Compare AddLife AB with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 17.75
2
Healthy long term growth as Net Sales has grown by an annual rate of 14.64% and Operating profit at 3.77%
3
With a growth in Net Profit of 220.99%, the company declared Outstanding results in Dec 25
Stock DNA
Pharmaceuticals & Biotechnology
SEK 17,057 Million (Small Cap)
62.00
NA
0.52%
0.73
10.49%
3.13
Revenue and Profits:
Net Sales:
2,733 Million
(Quarterly Results - Dec 2025)
Net Profit:
260 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.71%
0%
-15.71%
6 Months
-24.25%
0%
-24.25%
1 Year
-7.13%
0%
-7.13%
2 Years
23.58%
0%
23.58%
3 Years
52.17%
0%
52.17%
4 Years
-45.28%
0%
-45.28%
5 Years
-13.53%
0%
-13.53%
AddLife AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.64%
EBIT Growth (5y)
3.77%
EBIT to Interest (avg)
17.75
Debt to EBITDA (avg)
2.74
Net Debt to Equity (avg)
0.86
Sales to Capital Employed (avg)
0.98
Tax Ratio
34.80%
Dividend Payout Ratio
32.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.70%
ROE (avg)
13.77%
Valuation key factors
Factor
Value
P/E Ratio
62
Industry P/E
Price to Book Value
4.16
EV to EBIT
34.47
EV to EBITDA
16.78
EV to Capital Employed
2.66
EV to Sales
2.56
PEG Ratio
0.94
Dividend Yield
0.40%
ROCE (Latest)
7.71%
ROE (Latest)
6.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
2,733.00
2,429.00
12.52%
Operating Profit (PBDIT) excl Other Income
410.00
359.00
14.21%
Interest
50.00
54.00
-7.41%
Exceptional Items
0.00
0.00
Consolidate Net Profit
260.00
82.00
217.07%
Operating Profit Margin (Excl OI)
73.50%
65.90%
0.76%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 12.52% vs -5.78% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 217.07% vs -18.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
10,442.00
10,286.00
1.52%
Operating Profit (PBDIT) excl Other Income
1,589.00
1,532.00
3.72%
Interest
221.00
319.00
-30.72%
Exceptional Items
0.00
-10.00
100.00%
Consolidate Net Profit
562.00
254.00
121.26%
Operating Profit Margin (Excl OI)
74.70%
70.00%
0.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.52% vs 6.21% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 121.26% vs 32.29% in Dec 2024
About AddLife AB 
AddLife AB
Pharmaceuticals & Biotechnology
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
Company Coordinates 
Company Details
Brunkebergstorg 5, Box 3145 , STOCKHOLM None : 103 62
Registrar Details






